AstraZeneca says its Kovid-19 vaccine is ‘highly effective’ in late-stage trials

LONDON – Pharmaceutical company AstraZeneca said Monday late stage trials of the Kovid-19 vaccine were “highly effective” in preventing the disease.

The company said that developing the vaccine in collaboration with Britain’s University of Oxford prevented 70 percent of people from getting the disease. Researchers have also found that if people were given half the dose after one full dose, instead of two full doses, the protection increased to about 90 percent.

The results of AstraZeneca’s vaccine trials are the third promising success in the fight against the coronovirus pandemic that has killed nearly 1.4 million people and plundered the global economy.

Earlier this month, Pfizer and Moderna reported preliminary results from late-stage trials that showed their vaccine candidates were about 95% effective.

This is a developing story. Check back for updates.

Laura Saravia has contributed.

Leave a Reply

Your email address will not be published. Required fields are marked *